Sotera Health Company (Nasdaq: SHC) has announced its plans to hold an Investor Day in New York City, where the management team will discuss the company's strategic positioning and outline future growth plans. During the presentation, management will provide a detailed perspective of the markets served by the company and growth opportunities, including its serviceable addressable market of $18 billion.
CEO Michael J. Petras, Jr. highlighted the company's achievements over the past four years, including top* and bottom-line growth with strong margins, significant operating cash flow, disciplined capital deployment, and durable customer relationships. The company aims to achieve an organic compound annual revenue growth rate of 5% to 7% and expand Adjusted EBITDA margins by at least 50 basis points from 2025 to 2027. Additionally, Sotera Health plans to drive an organic compound annual Adjusted EBITDA growth rate of 5% to 8% and generate cumulative Free Cash Flow of more than $500 million during the same period.
Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, operating through three businesses – Sterigenics®, Nordion®, and Nelson Labs®.
Investors and stakeholders can access a live webcast of the event at the company's Presentation & Events page and are encouraged to pre-register for the webcast. The company also intends to make the investor presentation available concurrently with the start of the event and provide a replay of the video webcast within 48 hours following the conclusion of the event.
For further updates on recent developments, investors can visit the Investor Relations section of the company’s website. Following these announcements, the company's shares moved -3.9%, and are now trading at a price of $13.08. For more information, read the company's full 8-K submission here.
